In another study, Discovery Studio was used for molecular docking to identify the potential binding site of SIRT3 with craniospermone, revealing novel roles and mechanisms of craniospermone in anti-glomerular basement membrane antibody disease (GBM) and suggesting a new therapeutic approach for GBM treatment (Sun et al., 2022). Here, SIRT3 is linked to glioblastoma.